Bayer to collaborate on new treatments for tuberculosis with Universities of Dundee, Cape Town
March 8, 2016Manufacturing and Production, Research and Development Bayer, TB, tuberculosis, university of cape town, university of dundee
The pharmaceuticals division at German-based Bayer will collaborate with the renowned medicinal chemistry and biology departments at the Universities of …
Amgen open to larger M&A deals, says CFO
March 8, 2016Sales and Marketing Amgen, mergers and acquisitions
Amgen’s chief financial officer has indicated that the company is ready to consider doing larger deals to buy other companies, …
Sanofi Pasteur and MSD end European vaccines partnership
March 8, 2016Medical Communications, Research and Development, Sales and Marketing MSD, Sanofi Pasteur, Sanofi pasteur msd, vaccines
Sanofi Pasteur and MSD have announced that they will end their joint vaccines operations in Europe, bringing an end to …
Kuros Biosciences re-appoints chief medical officer
March 8, 2016Medical Communications
Kuros Biosciences has announced the appointment of Dr Virginia Jamieson as chief medical officer and member of the executive board …
Novartis and Microsoft team up for Kinect collab
March 8, 2016Manufacturing and Production, Research and Development Microsoft, Novartis, multiple sclerosis
Novartis has partnered with technology giant Microsoft; hoping to use its Kinect motion sensor to quantify whether its multiple sclerosis …
Merck posts 15% rise in Q4 profits driven by Sigma-Aldrich acquisition
March 8, 2016Manufacturing and Production, Sales and Marketing
German drug maker Merck on Tuesday said it sees the acquisition of Sigma-Aldrich to aid sales in 2016 and reported …
Wireless contact lens sensor approved by FDA
March 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing
The US Food and Drug Administration has allowed the marketing of a contact lens sensor that may help practitioners identify …
AbbVie pays $595m upfront for experimental Boehringer psoriasis drug
March 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, BI 655066, Boehringer Ingelheim, psoriasis
AbbVie is betting big on the future of an experimental psoriasis drug, paying $595m upfront for the rights to Boehringer …
Shares in Celldex halve in value as it discontinues trial of brain cancer drug
March 8, 2016Manufacturing and Production, Research and Development Cancer, Celldex, research
Shares in Celldex Therapeutics (Nasdaq: CLDX) more than halved in value on the Nasdaq Monday as the company said independent regulators …
Onconova says Baxalta ends $565 million drug development deal for rigosertib
March 8, 2016Manufacturing and Production, Research and Development Baxalta, Onconova Therapeutics, drug development, rigosertib
Onconova Therapeutics says Baxalta has terminated its $565 million agreement to jointly develop the company’s lead drug candidate rigosertib. Baxalta …
Merck says US FDA accepts its sBLA for Keytruda
March 8, 2016Manufacturing and Production, Research and Development Merck & Co, US FDA, keytruda, melanoma
US pharma giant Merck & Co said the US Food and Drug Administration (FDA) has accepted for review a new …
GSK says long-term study for Nucala backs safety profile
March 8, 2016Manufacturing and Production, Research and Development GSK, GlaxoSmithKline, Nucala, asthma
UK pharma major GlaxoSmithKline (LSE: GSK) said its asthma drug, Nucala (mepolizumab) showed a similar safety profile in a long-term …
EMA launches PRIME scheme
March 8, 2016Manufacturing and Production, Research and Development EMA, Guido Rasi, PRIME
The European Medicines Agency (EMA) has launched its new PRIME (priority medicines) scheme, which aims to strengthen support to medicines …
AstraZeneca’s Faslodex gets US FDA nod in combination treatment for breast cancer
March 8, 2016Manufacturing and Production, Research and Development AstraZeneca, Faslodex, US FDA, palbociclib
UK drug-maker AstraZeneca said the US Food and Drug Administration (FDA) has approved a new indication expanding the use of …
BMS criticises Scottish regulator over Opdivo skin cancer ‘no’
March 7, 2016Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo
Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …
AbbVie’s Imbruvica gets US FDA okay as first-line treatment for CLL
March 7, 2016Sales and Marketing AbbVie, Janssen, Janssen Biotech, US FDA, imbruvica
Drug maker AbbVie said the US Food and Drug Administration (FDA) has approved its Imbruvica (ibrutinib) as a first-line treatment …
Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials
March 7, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis
Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …
Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo
March 7, 2016Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo
Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …
Novo Nordisk reports five-year Victoza cardiovascular safety data
March 7, 2016Research and Development, Sales and Marketing Novo Nordisk, Victoza
Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …
FDA approves CSL Behring’s new haemophilia B treatment
March 7, 2016Research and Development, Sales and Marketing CSL Behring, haemophilia
The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
